Results Healthcare is delighted to have advised Sino Biopharmaceutical Limited, the leading innovative research and R&D-driven pharmaceutical group in China, on its acquisition of Softhale NV, a privately owned Belgian company focused on the development of products for the treatment of respiratory diseases.
Softhale’s next-generation Soft Mist Inhalation (“SMI”) device is based upon differentiated technology and allows for more efficient drug deposition into the lungs. The acquisition will enhance Sino Biopharmaceutical’s transformation from generics to an innovative player by acquiring and fully controlling its own respiratory research and development capability. It will also accelerate Sino Biopharmaceutical’s internationalisation strategy by establishing a local hub in Europe as well as developing products with significant global market potential.
This transaction is further testament to Results Healthcare’s expertise in the pharmaceutical and medical devices sectors and highlights the team’s strong relationships in the life sciences.